Blair William & Co. IL Has $3.07 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Blair William & Co. IL trimmed its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 3.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,714 shares of the biotechnology company’s stock after selling 4,566 shares during the quarter. Blair William & Co. IL owned about 0.16% of Rocket Pharmaceuticals worth $3,073,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its stake in shares of Rocket Pharmaceuticals by 31.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 764 shares in the last quarter. Old Well Partners LLC acquired a new position in Rocket Pharmaceuticals during the fourth quarter valued at approximately $200,000. Capstone Investment Advisors LLC bought a new position in shares of Rocket Pharmaceuticals in the fourth quarter valued at approximately $217,000. Virtu Financial LLC bought a new stake in shares of Rocket Pharmaceuticals during the 4th quarter worth $332,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Rocket Pharmaceuticals by 30.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,092 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 3,995 shares during the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Trading Down 5.6 %

Shares of RCKT stock opened at $20.17 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.79 and a current ratio of 7.79. The firm has a fifty day moving average of $20.61 and a 200-day moving average of $22.47. Rocket Pharmaceuticals, Inc. has a 52-week low of $16.55 and a 52-week high of $32.53. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -7.03 and a beta of 1.09.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.02). During the same period in the previous year, the company posted ($0.82) EPS. On average, equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RCKT has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. JPMorgan Chase & Co. raised their target price on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Canaccord Genuity Group dropped their price target on Rocket Pharmaceuticals from $49.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, July 3rd. Chardan Capital restated a “buy” rating and issued a $62.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, August 6th. Finally, William Blair reiterated an “outperform” rating on shares of Rocket Pharmaceuticals in a research note on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.29.

Insider Buying and Selling

In other Rocket Pharmaceuticals news, insider Mark Andrew White sold 3,026 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $20.39, for a total transaction of $61,700.14. Following the completion of the transaction, the insider now directly owns 72,220 shares in the company, valued at $1,472,565.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.10% of the stock is owned by corporate insiders.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.